Key takeaway
Shame can make you hide a return to use. NIDA says that return does not mean treatment failed. The plan should be resumed, changed, or replaced. Using a former dose after abstinence can cause overdose because the body is no longer adapted to it. Get medical care before you try to sort the guilt.
Last updated: Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
You used again, and the shame is loud enough to keep you from calling. NIDA's question is direct: does a return to drug use mean treatment has failed? The answer on its treatment page is no. Addiction is chronic. For some people, relapse, meaning a return to drug use after an attempt to stop, can be part of the process. Newer treatments are built to help prevent that return. NIDA also says relapse rates for drug use are similar to rates for other chronic medical illnesses. If people stop following a medical plan, they are likely to relapse. When it happens, the indicated step is to speak with a doctor about resuming treatment, changing it, or trying another one.
The medical risk does not wait on the shame. If breathing is slow, the person will not wake, or there is a seizure, call 911 before you arrange any program. For a mental health crisis, call or text 988.
The return itself can be the emergency
NIDA states that relapse can be deadly with some drugs. If a person uses as much of the drug as they did before quitting, they can overdose because their bodies are no longer adapted to the previous level of exposure. An overdose, in that description, is enough of a drug to produce uncomfortable feelings, life-threatening symptoms, or death.
SAMHSA's overdose page adds a specific warning for naltrexone. People using naltrexone for medication treatment of opioid use disorder have a reduced tolerance to opioids. Using the same dose as in the past, or even a lower dose, can be life-threatening. That warning also covers mixing opioids with alcohol, benzodiazepines, or other medicines.
If you have naloxone, use it when an opioid overdose is suspected, and stay until help arrives. The FDA approved a naloxone nasal spray for sale without a prescription. The overdose guide lists the signs NIDA and SAMHSA publish and the limits of naloxone, including that its effect can wear off while opioids are still in the body.
Alcohol and benzodiazepines need a clinician, not a promise to stop tonight
A return to heavy drinking or to regular benzodiazepine use is a different danger. "I will just stop" can be the harmful plan.
SAMHSA materials on alcohol use disorder describe withdrawal that can include seizures and delirium. TIP 45 says people with a history of severe withdrawal, delirium tremens, or seizures are not good candidates for detoxification in a nonmedical setting. Delirium tremens is described there as potentially fatal.
The FDA requires a boxed warning on benzodiazepines. Stopping them suddenly, or reducing the dose too fast, can cause seizures and other serious withdrawal reactions. The request to make after a relapse is a medical assessment, not unsupervised abstinence. The detox guide compares settings. It does not give a home schedule.
Medication is still the treatment, including after a return to use
NIDA says that when the addiction involves opioids, medication should be the first line of treatment, usually combined with some form of behavioral therapy or counseling. Medications are also available for alcohol and nicotine. For stimulants or cannabis, NIDA says no medications are currently available, so treatment is behavioral and should be matched to the person's pattern of use and related medical, mental, and social problems.
The opioid medications NIDA names are methadone, buprenorphine, and extended-release naltrexone. Lofexidine is listed for withdrawal symptoms. NIDA states that medications for opioid use disorder reduce the risk of overdose deaths. It also states that fewer than 1 in 5 people with opioid use disorder are treated with these medications. A return to use is not a reason to discard a medicine that reduces overdose deaths. It is a reason to contact the prescriber quickly about restarting, continuing, or changing the plan. Do not stop methadone, buprenorphine, or naltrexone on your own because you feel you no longer deserve it.
NIDA is explicit that detoxification is not the same as treatment and is not sufficient for recovery. Detoxification alone, without treatment afterward, generally leads to a return to drug use. If the next step is only "get through the withdrawal," the overdose risk after abstinence is still sitting there.
For alcohol, NIDA lists naltrexone, disulfiram, and acamprosate. Which of those fits is a clinician's decision. Starting, stopping, or combining them belongs with that clinician.
Behavioral therapies still matter beside medication. NIDA describes cognitive behavioral therapy as a way to recognize, avoid, and cope with situations tied to use. It describes contingency management as positive reinforcement for staying in treatment and meeting goals. Stress, people, places, things, and moods are named as common relapse cues, along with contact with the drug. A useful revision of the plan names the cue that showed up this time, instead of treating the return as a character verdict.
What to ask for today
Ask for an assessment that matches the substance and the medical risk. That might be withdrawal management, a restart of medication, outpatient care, or a higher level of care. FindTreatment.gov lists facilities by location. SAMHSA's National Helpline, 1-800-662-HELP (4357), is free, confidential, and available 24 hours a day for treatment referral. The guide on finding treatment explains the settings in SAMHSA's terms.
If a plan denies the restart, open the denial letter the same day. The appeals guide summarizes the internal appeal and external review that HealthCare.gov describes for many private plans. It also says Medicare and Medicaid publish their own processes. A referral conversation does not overturn a denial.
Call or text (800) 653-9376 if you want help sorting programs and a benefits question. Say whether this is a return to use after time away, and whether alcohol, a benzodiazepine, or an opioid is involved. That context changes the medical risk. It does not guarantee a bed.
What you might tell people close to you
You do not owe anyone a long confession before you get care. One sentence is enough: "I used again. I am getting an assessment." A program covered by federal substance-use confidentiality rules generally cannot confirm to relatives that you are admitted without your consent. The privacy guide explains that rule. You can still choose to tell a person who will drive you.
If you are the family member who just found out, skip the lecture tonight if the person is sick or scared. Offer the ride. If they might be overdosing, use the emergency number above. The same number is the one for a seizure or for someone who will not wake.
Additional Resources
Sources cited on this page:
- NIDA: Treatment and Recovery
- NIDA: Medications for Opioid Use Disorder
- SAMHSA: Opioid overdose prevention and reversal
- SAMHSA: Overdose Prevention and Response Toolkit
- SAMHSA TIP 45: Detoxification and Substance Abuse Treatment (settings and patient placement)
- SAMHSA: Medication for the Treatment of Alcohol Use Disorder - A Brief Guide
- FDA: Boxed warning to improve safe use of benzodiazepines
- FDA: Approval of the first over-the-counter naloxone nasal spray
- SAMHSA National Helpline
- SAMHSA FindTreatment.gov
- 988 Suicide & Crisis Lifeline
Common Questions
Does a relapse mean treatment failed?
NIDA says no. Because addiction is chronic, a return to use can be part of the course for some people. Relapse rates for drug use are similar to rates for other chronic illnesses. A return to use is a signal to speak with a clinician about resuming, changing, or trying another treatment.
Why is returning to opioids after a break so dangerous?
NIDA says that if a person uses as much of a drug as they did before quitting, they can overdose because the body is no longer adapted to the previous level of exposure. SAMHSA adds that people taking naltrexone have reduced opioid tolerance, so a dose that is the same or even lower than before can be life-threatening.
Should someone stop buprenorphine or methadone out of guilt?
NIDA says medication should be the first-line treatment for opioid addiction, usually combined with behavioral therapy or counseling, and that these medications reduce overdose deaths. A return to use is a reason to contact the prescriber promptly. Do not stop a prescribed medicine on your own to prove a point.
Is it safe to quit alcohol or benzodiazepines at home after a relapse?
It can be dangerous. SAMHSA's TIP 45 says people with severe alcohol withdrawal, delirium tremens, or seizures are not good candidates for a nonmedical setting. The FDA warns that stopping benzodiazepines abruptly can cause seizures. Ask for a medical assessment.
What if insurance will not restart care?
Ask the plan what the denial says and what deadline applies. The appeals guide describes the HealthCare.gov process for many private plans. Medicare and Medicaid use their own rules. A referral conversation can help you ask about other programs. Overturning a denial belongs to the plan's appeal process.